financetom
Business
financetom
/
Business
/
Chili's Parent Brinker Raises Full-Year Outlook After Strong Second-Quarter Results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chili's Parent Brinker Raises Full-Year Outlook After Strong Second-Quarter Results
Jan 29, 2025 10:07 AM

12:41 PM EST, 01/29/2025 (MT Newswires) -- Shares of Brinker International ( EAT ) soared intraday Wednesday after the casual dining restaurant operator boosted its fiscal 2025 guidance after reporting stronger-than-expected second-quarter results.

The parent of Chili's Grill & Bar ( EAT ) and Maggiano's Little Italy ( EAT ) now expects revenue to range between $5.15 billion and $5.25 billion, up from the $4.7 billion to $4.75 billion range it provided in October. Analysts surveyed by FactSet are modeling for revenue of $4.9 billion in the ongoing year.

Brinker's ( EAT ) adjusted earnings per share forecast was lifted to between $7.50 and $8 from a prior $5.20 to $5.50, well ahead of the $6.44 market expectation. The company's shares jumped about 14% in Wednesday midday trade.

For the three months ended Dec. 25, revenue jumped to $1.36 billion from $1.07 billion the year earlier and was roughly 9% above the FactSet consensus. Adjusted EPS advanced to $2.80 from $0.99 and was 51% above the Street's $1.86 view.

"Chili's ( EAT ) delivered another positive quarter in our turnaround and significantly outperformed the industry," Chief Executive Kevin Hochman told analysts on a conference call, according to a FactSet transcript. "We're pleased with our sustained momentum, the strength of the operational muscle we built, and our significantly improved Chili's ( EAT ) guest experience."

Consolidated comparable sales climbed 27.4% in the quarter, led by a 31.4% gain at Chili's ( EAT ) while Maggiano's sales were up 1.8%. Traffic improved nearly 20% at Chili's ( EAT ).

During the Q&A session on the call, Evercore ISI Senior Managing Director David Palmer described Brinker's ( EAT ) turnaround as probably "the best one of all time in the space."

Brinker ( EAT ) is continuing to work on driving efficiency, Hochman told analysts. Among those efforts are new kitchen display systems, the elimination of chicken portioning and a plan to convert the rest of the restaurant fleet to TurboChef ovens, which "rapidly accelerate cooking," he said.

Price: 176.82, Change: +22.21, Percent Change: +14.36

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Underlying Details of Canada's Unemployment Data Are A Bit Worrying, Says BMO
Underlying Details of Canada's Unemployment Data Are A Bit Worrying, Says BMO
Jun 12, 2025
07:09 AM EDT, 06/12/2025 (MT Newswires) -- The May employment figures for Canada were welcomed with a sigh of relief from markets, as they weren't nearly as weak as expected, said Bank of Montreal (BMO). Some parts of the report were encouraging, with big increases in full-time and private sector employment. Unfortunately, it wasn't all good news, noted the bank....
Merck Starts Phase 3 Trial of Dengue Vaccine
Merck Starts Phase 3 Trial of Dengue Vaccine
Jun 12, 2025
07:18 AM EDT, 06/12/2025 (MT Newswires) -- Merck & Co. ( MRK ) said Thursday that it initiated the MOBILIZE-1 phase 3 clinical trial evaluating V181 for the prevention of dengue. The company has started recruitment for the study, with the first participants now enrolling in Singapore. ...
Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH
Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH
Jun 12, 2025
07:15 AM EDT, 06/12/2025 (MT Newswires) -- Novartis ( NVS ) said Thursday that its phase 3b study of Fabhalta in adult patients with paroxysmal nocturnal hemoglobinuria, or PNH, showed statistically significant and clinically meaningful improvements in hemoglobin levels. The trial enrolled 52 patients who received Fabhalta for 24 weeks and the primary endpoint was change from baseline hemoglobin levels,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved